Base Genomics
Oxford
About Base Genomics
Base Genomics is an epigenetics company based on TAPS (TET-assisted pyridine borane sequencing), a new invention to sequence DNA methylation developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford. TAPS is a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike bisulfite sequencing, TAPS does not degrade DNA, meaning that more DNA is available for sequencing. It also retains sequence complexity, cutting sequencing costs and enabling simultaneous epigenetic and genetic analysis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $11.3M
- Funding stage: M&A
- Last round: Seed (Jun 2020)
- Website: basegenomics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/base-genomics-31022 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.